Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia

Leukemia

Volumn 26, Issue 12, 2012, Pages 2508-2516

  Merkel, O ^a   Wacht, N ^a   Sifft, E ^a   Melchardt, T ^a   Hamacher, F ^a   Kocher, T ^a   Denk, U ^a   Hofbauer, J P ^a   Egle, A ^a   Scheideler, M ^b   Schlederer, M ^c   Steurer, M ^d   Kenner, L ^c,e   Greil, R ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

actinomycin D; BCL2; CLL; del17p; MCL1; mouse model

Indexed keywords

CEPHAELINE; DACTINOMYCIN; FLUDARABINE; FUMONISIN B1; LASALOCID; NEOSOLANIOL; OCHRATOXIN; OLIGOMYCIN; PROTEIN BCL 2; PROTEIN P53;

ANIMAL EXPERIMENT; ARTICLE; CANCER SURVIVAL; CELL DEATH; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; GENE DELETION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; DACTINOMYCIN; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VIDARABINE;

EID: 84871213835     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.147     Document Type: Article

References (48)

1. Zenz T, Mertens D, Kuppers R, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
2. Zwiebel JA, Cheson BD. Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol 1998; 25: 42-59.
3. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmu-notherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443.
4. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995; 85: 1580-1589.
5. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
6. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
7. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799-804.
8. Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
9. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15: 995-1004.
10. Zenz T, Krober A, Scherer K, Habe S, Buhler A, Benner A et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008; 112: 3322-3329.
11. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, Agostinelli C et al. Alteration of BIRC3 and multiple other NF-kappaB pathway genes in splenic marginal zone lymphoma. Blood 2011; 118: 4930-4934.
12. Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012; 119: 521-529.
13. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376: 1164-1174.
14. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010: 481-488.
15. Zenz T, Mertens D, Dohner H, Stilgenbauer S. Importance of genetics in chronic lymphocytic leukemia. Blood Rev 2011; 25: 131-137.
16. Stilgenbauer S, Dohner H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med 2002; 347: 452-453.
17. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012-6018.
18. Phelps MA, Lin TS, Johnson AJ, Hurh E, Rozewski DM, Farley KL et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009; 113: 2637-2645.
19. Perry RP, Kelley DE. Inhibition of RNA synthesis by actinomycin D: characteristic dose-response of different RNA species. J Cell Physiol 1970; 76: 127-139.
20. Sobell HM. Actinomycin and DNA transcription. Proc Natl Acad Sci USA 1985; 82: 5328-5331.
21. Huang P, Sandoval A, Van Den NE, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 2000; 14: 1405-1413.
22. Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002; 99: 6955-6960.
23. Hofbauer JP, Heyder C, Denk U, Kocher T, Holler C, Trapin D et al. Development of CLL in the TCL1 transgenic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia 2011; 25: 1452-1458.
24. Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 2006; 108: 1334-1338.
25. Bertilaccio MT, Scielzo C, Simonetti G, Ponzoni M, Apollonio B, Fazi C et al. A novel Rag2-/-gammac-/-xenograft model of human CLL. Blood 2010; 115: 1605-1609.
26. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
27. Kuhn DM, Balkis M, Chandra J, Mukherjee PK, Ghannoum MA. Uses and limitations of the XTT assay in studies of Candida growth and metabolism. J Clin Microbiol 2003; 41: 506-508.
28. Merkel O, Heyder C, Asslaber D, Hamacher F, Tinhofer I, Holler C et al. Arsenic trioxide induces apoptosis preferentially in B-CLL cells of patients with unfavourable prognostic factors including del17p13. J Mol Med 2008; 86: 541-552.
29. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
30. Zanesi N, Aqeilan R, Drusco A, Kaou M, Sevignani C, Costinean S et al. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. Cancer Res 2006; 66: 915-920.
31. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009; 114: 4441-4450.
32. Lemoine FM, Humphries RK, Abraham SD, Krystal G, Eaves CJ. Partial characterization of a novel stromal cell-derived pre-B-cell growth factor active on normal and immortalized pre-B cells. Exp Hematol 1988; 16: 718-726.
33. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-13949.
34. Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005; 115: 369-378.
35. Pallasch CP, Schulz A, Kutsch N, Schwamb J, Hagist S, Kashkar H et al. Over-expression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood 2008; 112: 4213-4219.
36. Blagosklonny MV, Alvarez M, Fojo A, Neckers LM. bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. Leuk Res 1996; 20: 101-107.
37. Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2006; 103: 11713-11718.
38. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008; 112: 975-980.
39. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554-3561.
40. Pettitt AR, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441-1445.
41. Green DM. The treatment of stages I-IV favorable histology Wilms' tumor. J Clin Oncol 2004; 22: 1366-1372.
42. Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006; 107: 4109-4114.
43. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Mdm2 and Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006; 108: 993-1000.
44. Secchiero P, Barbarotto E, Tiribelli M, Zerbinati C, di Iasio MG, Gonelli A et al. Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006; 107: 4122-4129.
45. Kojima K, Duvvuri S, Ruvolo V, Samaniego F, Younes A, Andreeff M. Decreased sensitivity of 17p-deleted chronic lymphocytic leukemia cells to a small molecule BCL-2 antagonist ABT-737. Cancer 2012; 118: 1023-1031.
46. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006; 21: 749-760.
47. Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 2011; 471: 110-114.
48. Inuzuka H, Shaik S, Onoyama I, Gao D, Tseng A, Maser RS et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011; 471: 104-109.